Table 4 Effect of MSCs on CAR related product
From: The role of MSCs and CAR-MSCs in cellular immunotherapy
MSCs origin | MSCs modified | CAR type | Tumor cells | Effect on CAR response | Ref |
|---|---|---|---|---|---|
BM of MM patients | / | BCMA.CAR-T cells CD38.CAR-T cells CD138.CAR-T cells | MM | Protect the lysis by low affinity, moderately lystic CAR; More killed by high affinity, strongly lytic CAR | [124] |
BM of B-ALL patients. BM of Health donor | / | CD19.CAR-T cells | B-ALL | Inhibiting the growth of B-ALL | [125] |
BM of Health donor | CAd.MSCs | HER2.CAR-T | A549、H1650 lung cancer cell lines | Increase the cytotoxicity | [13] |
BM of Health donor | IL-2.IL7.MSCs | CEA.CAR-T cells | LS174T colorectal cancer cells | Both non-modified and modified MSCs can improve the cytotoxicity. The modified MSCs have higher cytotoxicity | [16] |
BM of MM patients | / | CD38.CAR-T cells | RPMI-8226 and MM1.s MM cell lines | Increase the lysis | [129] |